公开(公告)号：US11266762B2

公开(公告)日：2022-03-08

申请号：US16294698

申请日：2019-03-06

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Alistair Simpson Irvine ,  Philippe Paul Saudan

IPC分类号： A61L24/10 ,  A61L27/22 ,  A61L27/54

摘要： Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

公开(公告)号：US20190275197A1

公开(公告)日：2019-09-12

申请号：US16294698

申请日：2019-03-06

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Alistair Simpson Irvine ,  Philippe Paul Saudan

IPC分类号： A61L24/10

摘要： Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

公开(公告)号：US09180222B2

公开(公告)日：2015-11-10

申请号：US14598786

申请日：2015-01-16

申请人： Kuros Biosurgery AG

发明人： Annemie Rehor Kausch ,  Simona Cerritelli

IPC分类号： A61K31/74 ,  A61L24/04 ,  A61L31/06 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08L71/02 ,  A61L24/00 ,  C08G63/00 ,  A61K47/34

CPC分类号： A61L24/046 ,  A61K47/34 ,  A61L24/0042 ,  A61L31/06 ,  A61L2400/04 ,  C08G63/00 ,  C08G65/3322 ,  C08G65/33306 ,  C08G65/3342 ,  C08G2650/58 ,  C08L71/02 ,  C08L2666/22

摘要： Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein: i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2 ii) the second precursor molecule is of the general formula: A-[(C3H6O)n—(C2H4O)m—B]i wherein m and n are integers from 1 to 200 i is greater than 2 A is a branch point B is a conjugated unsaturated group The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.

公开(公告)号：US20030232944A1

公开(公告)日：2003-12-18

申请号：US10395650

申请日：2003-03-21

申请人： Kuros Biosurgery AG ,  Straumann Biologics AG

发明人： Aaldert Rens Molenberg ,  Daniel Fehr ,  Enrico Zamparo

IPC分类号： C08G077/00 ,  C08G077/06

CPC分类号： A61L27/16 ,  A61L27/50 ,  A61L2430/02

摘要： Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).

公开(公告)号：US20220331110A1

公开(公告)日：2022-10-20

申请号：US17762223

申请日：2020-09-21

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Philippe Paul Saudan ,  Alistair Simpson Irvine

IPC分类号： A61F2/28 ,  A61L27/54 ,  A61F2/44 ,  A61L27/48 ,  A61L27/22 ,  A61F2/46

摘要： The invention concerns a bone graft material for use in a spinal fusion method, wherein the material comprises i) a composition for forming a matrix, comprising at least a first matrix material precursor component and a second matrix material precursor component, capable of forming a matrix by crosslinking of the precursor components under appropriate conditions; and ii) a bioactive factor, which is biologically active to stimulate bone formation between two vertebrae, and for effecting or supporting spinal fusion; wherein the spinal fusion method comprises the steps of applying a cage in between the two vertebrae, which is not pre-filled with the bone graft material; and subsequently applying the bone graft material adjacent to and/or into the cage, such that essentially the entire remaining volume between the two vertebrae is filled with the bone graft material. The invention allows for ease of use while forming a more homogeneous matrix.

公开(公告)号：US20220202987A1

公开(公告)日：2022-06-30

申请号：US17671463

申请日：2022-02-14

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Alistair Simpson Irvine ,  Philippe Paul Saudan

IPC分类号： A61L24/10 ,  A61L27/54

摘要： Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

公开(公告)号：US20150133579A1

公开(公告)日：2015-05-14

申请号：US14598786

申请日：2015-01-16

申请人： Kuros Biosurgery AG

发明人： Annemie Rehor ,  Simona Cerritelli

IPC分类号： A61L24/04 ,  C08G63/00 ,  A61L24/00

CPC分类号： A61L24/046 ,  A61K47/34 ,  A61L24/0042 ,  A61L31/06 ,  A61L2400/04 ,  C08G63/00 ,  C08G65/3322 ,  C08G65/33306 ,  C08G65/3342 ,  C08G2650/58 ,  C08L71/02 ,  C08L2666/22

摘要： Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein: i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2 ii) the second precursor molecule is of the general formula: A-[(C3H6O)n—(C2H4O)m—B]i wherein m and n are integers from 1 to 200 i is greater than 2 A is a branch point B is a conjugated unsaturated group The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.

摘要翻译： 用于制备用作组织密封剂的生物材料的方法，包含用于形成生物材料的前体的试剂盒以及所得生物材料在本文中描述。 生物材料由包含至少第一和第二前体分子的组合物形成，其中：i）第一前体分子是具有选自硫醇或氨基的x个亲核基团的聚（乙二醇）基聚合物， 其中x大于或等于2 ii）第二前体分子具有以下通式：A - [（C 3 H 6 O）n - （C 2 H 4 O）m -B] i，其中m和n是1至200i的整数更大 优于2 A是分支点B是共轭不饱和基团根据生物材料的所需性质选择前体。 任选地，生物材料含有添加剂，例如触变剂，不透射线剂或生物活性剂。 在优选的实施方案中，生物材料用于减少，抑制或含有患者体内的生物流体或气体的损失。